Cargando…

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Objective: We aimed to evaluate the efficacy of canagliflozin for the treatment of specific cardiovascular and renal outcomes in Type 2 diabetes mellitus (T2DM) patients by means of a systematic review and meta-analysis. Methods: We performed comprehensive searches of PubMed, the Cochrane Library, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Lei, Cai, Yuzi, Zheng, Huijuan, Ai, Sinan, Zhou, Mengqi, Luo, Qian, Tang, Jingyi, Liu, Weijing, Wang, Yaoxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327383/ https://www.ncbi.nlm.nih.gov/pubmed/34349651 http://dx.doi.org/10.3389/fphar.2021.691878

Ejemplares similares

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
por: Tian, Lei, et al.
Publicado: (2022)

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease
por: Wang, Xueliang, et al.
Publicado: (2022)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2019)

Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition
por: Wang, Jian, et al.
Publicado: (2023)

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
por: He, Lili, et al.
Publicado: (2022)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis
por: Luo, Qian, et al.
Publicado: (2022)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
por: Zheng, Cankun, et al.
Publicado: (2022)

Canagliflozin alleviates valproic acid-induced autism in rat pups: Role of PTEN/PDK/PPAR-γ signaling pathways
por: Elgamal, Mariam A., et al.
Publicado: (2023)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Cordyceps cicadae Ameliorates Renal Hypertensive Injury and Fibrosis Through the Regulation of SIRT1-Mediated Autophagy
por: Cai, Yuzi, et al.
Publicado: (2022)

Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1
por: Niu, Yaoyun, et al.
Publicado: (2022)

Renal Protective Effects of Melatonin in Animal Models of Diabetes Mellitus-Related Kidney Damage: A Systematic Review and Meta-Analysis
por: Luo, Qian, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Targeting ferroptosis as novel therapeutic approaches for epilepsy
por: Jin, Yuzi, et al.
Publicado: (2023)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
por: Mahaffey, Kenneth W., et al.
Publicado: (2019)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials
por: Lei, Hong, et al.
Publicado: (2016)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms
por: Hao, Wenhui, et al.
Publicado: (2022)

Bibliometric visualization analysis of gut-kidney axis from 2003 to 2022
por: Ai, Sinan, et al.
Publicado: (2023)

Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis
por: Chen, Yao-Yao, et al.
Publicado: (2021)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Natural AMPK Activators in Cardiovascular Disease Prevention
por: Heidary Moghaddam, Reza, et al.
Publicado: (2022)

Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases
por: Zhou, Yan-Xi, et al.
Publicado: (2021)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Periplocymarin Plays an Efficacious Cardiotonic Role via Promoting Calcium Influx
por: Yun, Weijing, et al.
Publicado: (2020)

The effect of tacrolimus conversion from immediate- to extended-release formulation on renal function in renal transplant patients: a meta-analysis
por: Chao, Sheng, et al.
Publicado: (2023)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease
por: Wang, Yinghui, et al.
Publicado: (2022)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice
por: Zhu, Qian, et al.
Publicado: (2023)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
por: Skelley, Jessica W, et al.
Publicado: (2018)

Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study
por: Udell, Jacob A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kbnf69davbtdv26j51k7drfe2r